AustralianSuper Pty Ltd Lowers Stock Holdings in Bristol Myers Squibb Company $BMY

AustralianSuper Pty Ltd reduced its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 27.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,361,163 shares of the biopharmaceutical company’s stock after selling 871,756 shares during the period. AustralianSuper Pty Ltd owned about 0.12% of Bristol Myers Squibb worth $106,488,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Bristol Myers Squibb by 4.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,211,845 shares of the biopharmaceutical company’s stock valued at $99,754,000 after buying an additional 93,528 shares during the period. Retirement Planning Co of New England Inc. lifted its stake in shares of Bristol Myers Squibb by 3.2% in the 3rd quarter. Retirement Planning Co of New England Inc. now owns 11,575 shares of the biopharmaceutical company’s stock valued at $522,000 after acquiring an additional 363 shares during the last quarter. Mystic Asset Management Inc. boosted its holdings in Bristol Myers Squibb by 2.3% during the 3rd quarter. Mystic Asset Management Inc. now owns 24,658 shares of the biopharmaceutical company’s stock valued at $1,112,000 after acquiring an additional 566 shares during the period. Little House Capital LLC grew its position in Bristol Myers Squibb by 5.2% during the 3rd quarter. Little House Capital LLC now owns 26,319 shares of the biopharmaceutical company’s stock worth $1,187,000 after acquiring an additional 1,291 shares during the last quarter. Finally, Pines Wealth Management LLC purchased a new position in Bristol Myers Squibb in the 3rd quarter worth approximately $204,000. 76.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on BMY shares. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their target price for the stock from $52.00 to $61.00 in a report on Monday, December 15th. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Finally, Leerink Partners boosted their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Seven equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $57.43.

Bristol Myers Squibb Trading Down 1.6%

NYSE BMY opened at $54.66 on Thursday. The firm has a market capitalization of $111.26 billion, a PE ratio of 18.46, a P/E/G ratio of 0.17 and a beta of 0.29. The stock’s 50 day moving average is $53.07 and its 200 day moving average is $48.55. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same quarter last year, the firm posted $1.80 earnings per share. The company’s revenue for the quarter was up 2.8% on a year-over-year basis. Research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be given a dividend of $0.63 per share. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date of this dividend is Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.6%. Bristol Myers Squibb’s dividend payout ratio is 85.14%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.